The Company has notified the NYSE that it intends to submit a plan to regain compliance within 45 days of the notice received on November 15, 2023 advising the NYSE of definitive action it has or will take to regain compliance. If the NYSE accepts the Company’s plan, the Company’s common stock, par value $0.001 per share (the “Common Stock”), may continue to be listed and traded on the NYSE during the 18-month cure period, subject to the Company’s pending NYSE appeal and hearing determination.
This doesn’t say anything about having to be a specific price if the NYSE re lists them.
Just says “may continue to be listed “
At that point they would have to THROW THE KITCHEN SINK and try to get the share price up. Hopefully they have the ammunition
News 
Market Data 
Discover 
AI
